Role of poly(ADP-ribose) synthetase in pulmonary leukocyte recruitment.
During systemic inflammation, recruitment and activation of leukocytes in the pulmonary microcirculation may result in a potentially life-threatening acute lung injury. We elucidated the role of the poly(ADP-ribose) synthetase (PARS), a nucleotide-polymerizing enzyme, in the regulation of leukocyte recruitment within the lung with regard to the localization in the pulmonary microcirculation and in correlation to hemodynamics in the respective vascular segments and expression of intercellular adhesion molecule 1 during endotoxemia. Inhibition of PARS by 3-aminobenzamide reduced the endotoxin-induced leukocyte recruitment within pulmonary arterioles, capillaries, and venules in rabbits as quantified by in vivo fluorescence microscopy. Microhemodynamics and thus shear rates in all pulmonary microvascular segments remained constant. Simultaneously, inhibition of PARS with 3-aminobenzamide suppressed the endotoxin-induced adhesion molecules expression as demonstrated for intercellular adhesion molecule 1 by immunohistochemistry and Western blot analysis. We confirmed this result with the use of PARS knockout mice. The inhibitory effect of 3-aminobenzamide on leukocyte recruitment was associated with a reduction of pulmonary capillary leakage and edema formation. We first provide evidence that PARS activation mediates the leukocyte sequestration in pulmonary microvessels through upregulation of adhesion molecules. As reactive oxygen species released from leukocyte are supposed to cause an upregulation of adhesion molecules we conclude that PARS inhibition contributes to termination of this vicious cycle and inhibits the inflammatory process.
Kiefmann
Rainer
R
Department of Anesthesiology, University of Munich, 81377 Munich, Germany.
Heckel
Kai
K
Dörger
Martina
M
Schenkat
Sonja
S
Stoeckelhuber
Mechthild
M
Wesierska-Gadek
Józefa
J
Goetz
Alwin E
AE
D000818:Animals; D001160:Arterioles / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D001549:Benzamides / Q000494:pharmacology; D001783:Blood Flow Velocity / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002448:Cell Adhesion / Q000502:physiology*; D004487:Edema / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004912:Erythrocytes / Q000502:physiology; D006439:Hemodynamics / Q000502:physiology*; D007962:Leukocytes / Q000502:physiology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008168:Lung / Q000502:physiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000172:deficiency / Q000378:metabolism*; D011652:Pulmonary Circulation / Q000502:physiology*; D011817:Rabbits
D001549:Benzamides; D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C025160:3-aminobenzamide; D011065:Poly(ADP-ribose) Polymerases